Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that poster and expert presentations featuring MEDIHONEY ® and XTRASORB ®, two of the commercial products in the Company’s full line of advanced wound care dressings, were highlighted at the Symposium on Advanced Wound Care (SAWC) Spring 2011 held in Dallas April 14 -17.

Derma Sciences MEDIHONEY ® poster by Cynthia Bridgman BSN, RN, CWOCN and Carol Hall BSN, RN, CWOCN, CFCN, of The University of Texas Southwestern Medical Center at Dallas was awarded first place poster in the case series category by SAWC.

Tiffney D. Oliver, Director, Educational Services, North American Center for Continuing Medical Education, LLC, stated “Close to 300 abstracts were accepted as posters for SAWC based on a blind, peer-review by judges who are experts in the field. Of those, 107 were case studies. All abstracts were reviewed based on specific criteria for the category in which it was placed and the highest scoring case study award represented the case study that received the highest overall score within its category by our judges.”

The following posters featuring MEDIHONEY ® and XTRASORB ® were presented at SAWC.
  • Use of Active Leptospermum Honey to Heal Pressure Ulcers – A Case Series of Pressure Ulcer Patients Cynthia Bridgman BSN, RN, CWOCN and Carol Hall BSN, RN, CWOCN, CFCN, The University of Texas Southwestern Medical Center at Dallas
  • Protease Modification by Super Absorbent Polymer Dressings Marcy Turkos, PT, DPT, CWS; Kimberly Stallo, BS, RN, CWOCN, Derma Sciences, Princeton, NJ

The following presentations highlighting MEDIHONEY ® and XTRASORB ® were presented at the Derma Sciences booth during SAWC:
  • The Versatility of MEDIHONEY® for Use on a Variety of Stalled Wounds and Wounds of Atypical Etiologies Basit Ali, DO, Medical Director, Wound Healing & Hyperbaric Center, Methodist Charlton Medical Center, Dallas, TX
  • MEDIHONEY® and XTRASORB® The Value of an Osmotic Gradient on Chronic Wounds: A Combination Therapy Kim L. Peters, RN, CWS, Whittier Rehabilitation Hospital, Bradford, MA

Commenting on the Company’s presentations, Edward J. Quilty, chairman and CEO of Derma Sciences, states, “We were excited to share these MEDIHONEY ® and XTRASORB ® posters and presentations at SAWC and are extremely honored to have had our MEDIHONEY ® case series recognized as best poster by experts in the field. SAWC is the largest annual gathering of wound care clinicians in the United States and it is crucial for sharing information aimed at empowering the medical community to elevate patient care while showcasing the advantages of our advanced wound care products.”

MEDIHONEY®, the leading global brand of honey-based wound care, is a line of wound and burn dressings containing active Manuka (Leptospermum) honey from New Zealand. This unique species of medical-grade honey has been shown in several large-scale, randomized controlled clinical studies to possess unique qualities that help to initiate healing in stalled wounds, and assist with fast debridement of non-viable tissue. Last month the Company received 510(k) clearance from the U.S. Food and Drug Administration for MEDIHONEY Gel, which is dispensed from a tube and contains patent pending gelling agents that allow the honey to better to better maintain its physical integrity at the site of the wound, even in the presence of wound fluid and body heat.

XTRASORB® is a line of novel super-absorbent wound dressings. The core super-absorbent polymer technologies dramatically improve the capabilities of the dressings versus conventional moist wound dressings. Whereas other absorbent dressings (including foams, absorbent pads, and other cellulose-based dressings) rely on spaces within the dressings to fill with fluid, XTRASORB®’s super-absorbent polymers bind fluid and convert it to a gel. This dramatically increases the absorptive capability of the dressings, while also helping to reduce the risk of maceration and exposure to the harmful components within wound fluid (such as bacteria and proteases).

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention. For more information please visit www.dermasciences.com.

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.

Copyright Business Wire 2010